A central arteriovenous fistula reduces systemic hypertension in a mouse model

Q3 Medicine

JVS-vascular science Pub Date : 2024-01-01 DOI:10.1016/j.jvssci.2024.100191

Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁幸彦) MD , Yuichi Ohashi (大橋雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD

{"title":"A central arteriovenous fistula reduces systemic hypertension in a mouse model","authors":"Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁幸彦) MD , Yuichi Ohashi (大橋雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD","doi":"10.1016/j.jvssci.2024.100191","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.</p></div><div><h3>Methods</h3><p>A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.</p></div><div><h3>Results</h3><p>In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.</p></div><div><h3>Conclusions</h3><p>These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.</p></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"5 ","pages":"Article 100191"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666350324000026/pdfft?md5=60786e70b011585e96e3a0ee22d68666&pid=1-s2.0-S2666350324000026-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JVS-vascular science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666350324000026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.

Methods

A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.

Results

In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.

Conclusions

These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.

Abstract Image

查看原文本刊更多论文

中心动静脉瘘可降低小鼠模型的全身性高血压

目的中心动静脉瘘（AVF）被认为是治疗难治性高血压患者的一种潜在的新方法。我们假设，与正常血压环境下的重塑相比，在高血压环境下创建 AVF 后的静脉重塑可降低全身血压，但会导致 AVF 壁厚度增加。方法在先前用血管紧张素 II（Ang II）使之变为高血压的 C57BL6/J 小鼠中实施中心动静脉瘘；术后第 7 天或第 21 天处死小鼠。结果在单独使用血管紧张素 II 治疗的小鼠中，平均收缩压从 90 ± 5 mmHg 上升到第 21 天的 160 ± 5 mmHg；但在同时使用血管紧张素 II 和动静脉瘘治疗的小鼠中，血压随着动静脉瘘的建立而下降。与正常血压小鼠相比，有 AVF 的高血压小鼠 PCNA 阳性细胞、SM22α/PCNA 阳性细胞、胶原 I 沉积明显增多，Krüppel 样因子 2 免疫活性也有所提高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JVS-vascular science

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

28 weeks